Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, has announced the signature of a collaboration with The Swiss Group for Clinical Cancer Research (SAKK) to conduct a Phase-II randomized clinical trial in early-stage triple negative breast cancer (TNBC) patients in Europe. The trial will evaluate INT230-6, Intensity Therapeutics' lead drug candidate.

Lewis H. Bender, Founder, President, and CEO of Intensity Therapeutics, expressed his enthusiasm, stating, "We are excited to be working with SAKK on our INVINCIBLE-4 Study in early-stage triple-negative breast cancer. TNBC poses significant challenges due to its aggressiveness, high relapse rates, and increased mortality, especially in patients with large tumors."

The collaboration aims to address these challenges by assessing the efficacy and safety of INT230-6 in treating early-stage TNBC, providing hope for patients and advancing treatment options for this aggressive form of breast cancer.